GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Simris Alg AB (OSTO:SIMRIS B) » Definitions » Debt-to-EBITDA

Simris Alg AB (OSTO:SIMRIS B) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Simris Alg AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Simris Alg AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Simris Alg AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Simris Alg AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-21.30 Mil. Simris Alg AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Simris Alg AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:SIMRIS B' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.68   Med: -0.21   Max: 0
Current: -0.12

OSTO:SIMRIS B's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs OSTO:SIMRIS B: -0.12

Simris Alg AB Debt-to-EBITDA Historical Data

The historical data trend for Simris Alg AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simris Alg AB Debt-to-EBITDA Chart

Simris Alg AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.19 -0.14 -0.12 -0.12

Simris Alg AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.12 -

Competitive Comparison of Simris Alg AB's Debt-to-EBITDA

For the Biotechnology subindustry, Simris Alg AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simris Alg AB's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Simris Alg AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Simris Alg AB's Debt-to-EBITDA falls into.



Simris Alg AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Simris Alg AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.207 + 1.462) / -22.363
=-0.12

Simris Alg AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Simris Alg AB  (OSTO:SIMRIS B) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Simris Alg AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Simris Alg AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Simris Alg AB (OSTO:SIMRIS B) Business Description

Traded in Other Exchanges
Address
Herrestadsvagen 24A, Hammenhog, SWE, 276 50
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.

Simris Alg AB (OSTO:SIMRIS B) Headlines

No Headlines